CoChat

Treatment choices and neuropsychological symptoms of a large cohort of early MS

Open access
von Bismarck, Olga, Dankowski, Theresa, Ambrosius, Björn, Hessler, Nicole, Antony, Gisela, Ziegler, Andreas, Hoshi, Muna-Miriam, Aly, Lilian, Luessi, Felix, Groppa, Sergiu, Klotz, Luisa, Meuth, Sven G., Tackenberg, Björn, Stoppe, Muriel, Then Bergh, Florian, Tumani, Hayrettin, Kümpfel, Tania, Stangel, Martin, Heesen, Christoph, Wildemann, Brigitte, Paul, Friedemann, Bayas, Antonios, Warnke, Clemens, Weber, Frank, Linker, Ralf A., Ziemann, Ulf, Zettl, Uwe K., Zipp, Frauke, Wiendl, Heinz, Hemmer, Bernhard, Gold, Ralf, Salmen, Anke · 2018 · Neurology Neuroimmunology & Neuroinflammation
Cited by 67

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: To assess clinical characteristics, distribution of disease-modifying treatments (DMTs), and neuropsychological symptoms in a large cohort of patients with early-stage MS. METHODS: The German National MS Cohort is a multicenter prospective longitudinal cohort study that has recruited DMT-naive patients with clinically isolated syndrome (CIS) and relapsing-remitting MS (RRMS) since 2010. We evaluated their baseline characteristics and the prevalence of neuropsychological symptoms. RESULTS: Of 1,124 patients, with a 2.2:1 female-to-male ratio and median age at onset of 31.71 years (interquartile range [IQR]: 26.06-40.33), 44.6% and 55.3% had CIS and RRMS, respectively. The median Expanded Disability Status Scale (EDSS) score at baseline was 1.5 (IQR: 1.0-2.0). A proportion of 67.8% of patients started DMT after a median time of 167.0 days (IQR 90.0-377.5) since the first manifestation. A total of 64.7% and 70.4% of the 762 patients receiving early DMT were classified as CIS and RRMS, respectively. Fatigue, depressive symptoms, and cognitive dysfunction were detected in 36.5%, 33.5%, and 14.7% of patients, respectively. CONCLUSION: Baseline characteristics of this large cohort of patients with early, untreated MS corroborated with other cohorts. Most patients received early DMT within the first year after disease onset, irrespective of a CIS or RRMS diagnosis. Despite the low EDSS score, neuropsychological symptoms affected a relevant proportion of patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/nxi.0000000000000446

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 67

Metadata

Authors
von Bismarck, O., Dankowski, T., Ambrosius, B., Hessler, N., Antony, G., Ziegler, A., Hoshi, M.-M., Aly, L., Luessi, F., Groppa, S., Klotz, L., Meuth, S. G., Tackenberg, B., Stoppe, M., Then Bergh, F., Tumani, H., Kümpfel, T., Stangel, M., Heesen, C., Wildemann, B., Paul, F., Bayas, A., Warnke, C., Weber, F., Linker, R. A., Ziemann, U., Zettl, U. K., Zipp, F., Wiendl, H., Hemmer, B., Gold, R., & Salmen, A.
Venue
Neurology Neuroimmunology & Neuroinflammation
Published
2018-05
Volume
5
Issue
3
Pages
e446-e446
ISSN
2332-7812 (ISSN-L)
OpenAlex
W2793659448
Cited by
67
References
9
FWCI
7.23
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Treatment choices and neuropsychological symptoms of a large cohort of early MS. https://app.cochat.ai/papers/10.1212/nxi.0000000000000446
The paper
von Bismarck, O., Dankowski, T., Ambrosius, B., Hessler, N., Antony, G., Ziegler, A., Hoshi, M.-M., Aly, L., Luessi, F., Groppa, S., Klotz, L., Meuth, S. G., Tackenberg, B., Stoppe, M., Then Bergh, F., Tumani, H., Kümpfel, T., Stangel, M., Heesen, C., . . . Salmen, A. (2018). Treatment choices and neuropsychological symptoms of a large cohort of early MS. Neurology Neuroimmunology & Neuroinflammation. https://doi.org/10.1212/nxi.0000000000000446

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.